16.69 USD
▼-0.62-0.71%
盘后 16.81 0.00%
2026-08-03
市值
$1.52B
市盈率
—
EPS
-0.50
股息率
—
52 周区间
16.36 – 48.45
成交量
5.54K
Beta
0.66
目标价
47.56
52W 低 16.3652W 高 48.45
价格走势
公司简介
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid...